Hôpitaux Universitaires Strasbourg - Hôpital de Hautepierre

At Hôpitaux Universitaires Strasbourg - Hôpital de Hautepierre the Medical Oncology department leads extensive research on a range of solid cancers, testing new systemic therapies and evaluating innovative treatment combinations to improve survival and quality of life.

• Advanced non‑small cell lung cancer
• Metastatic renal cell carcinoma
• Hepatocellular carcinoma
• Breast cancer (ER+/HER2‑)
• Colorectal and gastric cancers
• Sarcomas including osteosarcoma and Ewing sarcoma

The site supports 663 active trials with 19 investigators, focusing on novel immunotherapies, targeted agents and peri‑operative strategies.

Research in blood‑borne malignancies targets both acute and chronic diseases, aiming to refine transplant protocols and introduce antibody‑based treatments that can enhance remission rates.

• Acute myeloid leukemia
• Acute lymphoblastic leukemia
• Chronic lymphocytic leukemia
• Multiple myeloma
• Hodgkin and non‑Hodgkin lymphoma

Trials evaluate CAR‑T cells, bispecific antibodies and novel chemotherapy‑free regimens while monitoring long‑term graft‑versus‑host disease outcomes.

The department conducts studies on systemic immune diseases, testing biologics and steroid‑sparing approaches to reduce organ damage and improve patient‑reported outcomes.

• Systemic lupus erythematosus
• Rheumatoid arthritis
• ANCA‑associated vasculitis
• Idiopathic inflammatory myopathies
• Sjögren’s syndrome
• Inflammatory bowel disease

Innovative agents such as anti‑CD20, IL‑6 blockers and JAK inhibitors are under evaluation in well‑characterized patient cohorts.

Cardiovascular trials address acute events, chronic heart failure and metabolic risk factors, exploring new lipid‑lowering drugs, RAAS inhibitors and lifestyle‑integrated therapies.

• Acute coronary syndrome
• Chronic heart failure
• Atherosclerotic cardiovascular disease
• Hypertension and resistant hypertension
• Obesity and metabolic syndrome
• Metabolic dysfunction‑associated steatohepatitis (MASH)

Outcomes focus on mortality, hospitalisation rates and improvements in cardiac function or liver fibrosis.

Trials in respiratory medicine evaluate severe asthma, chronic obstructive pulmonary disease and emerging infectious threats, seeking therapies that reduce exacerbations and improve lung function.

• Severe eosinophilic asthma
• Chronic obstructive pulmonary disease
• COVID‑19 and post‑viral sequelae
• Nontuberculous mycobacterial lung infection
• Pulmonary hypertension
• Interstitial lung disease related to systemic sclerosis

Studies also incorporate advanced imaging and biomarker strategies to tailor treatment intensity.

Neurological research focuses on progressive disorders, evaluating disease‑modifying agents and precision diagnostics to slow cognitive decline and motor impairment.

• Early Alzheimer’s disease
• Parkinson’s disease
• Multiple sclerosis (relapsing and progressive forms)
• Diffuse intrinsic pontine glioma
• Epilepsy and focal onset seizures

Trials often combine immunotherapy with neuroprotective compounds and assess long‑term functional outcomes.

Children and adolescents are enrolled in trials targeting high‑risk solid tumours and rare malignancies, with an emphasis on reducing treatment toxicity while maintaining efficacy.

• High‑risk neuroblastoma
• Medulloblastoma
• Ewing sarcoma
• Wilms tumor
• Rare central nervous system tumors
• Advanced sarcomas with molecular alterations

Innovative approaches include metronomic chemotherapy, targeted inhibitors and early‑phase immunotherapies.

The site integrates cutting‑edge diagnostic tools and procedural innovations to enhance patient selection and treatment delivery across specialties.

• Contrast‑enhanced ultrasound for adnexal torsion
• Gadolinium‑based contrast safety in MRI
• Molecular profiling for targeted therapy allocation
• Minimally invasive surgical techniques
• Advanced anesthesia monitoring and analgesia
• Real‑time therapeutic drug monitoring

These technologies support personalized medicine initiatives and improve trial efficiency.